Aislinn Antrim, Managing Editor

Eligible patients can receive a 30-day supply of covered drugs and medical supplies that can be renewed every 30 days for as long as an Emergency Prescription Assistance Program (EPAP) is active.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Notably, of the 38 participants who remained on treatment, 37 have switched to less frequent dosing and all have maintained responses.

The approval enables more convenient flu immunization options for patients.

Amivatamab-vmjw is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directed activity.

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

FCS is a severe, rare genetic disease in which patients have extremely high triglyceride levels, typically above 880 mg/dL.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.

New payment frameworks are emerging, but pharmacists need to be central to the ongoing food as medicine movement.

Educate patients about the importance of vaccination in preventing severe disease.

Pharmacists Can Help Patients Select Probiotic Products and Advise Them on When to Seek Further Care.

Hyperhidrosis affects an estimated 10 million individuals in the US and is characterized by abnormally increased sweating, beyond what is necessary to regulate body temperature.

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.

With the new ruling, announced Thursday, the pills will continue to be able to be mailed to patients without an in-person visit with a physician.1

Imetelstat (Rytelo; Geron Corp) is a first-in-class telomerase inhibitor.

The panelists expressed concerns about clinical trial data and concluded that the benefits do not outweigh the risks, but the FDA does not have to follow their recommendation.

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

Although this data seems to overwhelmingly suggest that cannabis use has negative impacts for individuals with multiple sclerosis (MS), listening to patients’ reasoning for using it is crucial.

Subcutaneous ocrelizumab can be delivered in approximately 10 minutes and deliver comparable clinical benefit and safety to the IV formulation.

Although resources were scarce for teams at smaller private practices, the pharmacists all agreed that patient care is always the priority.

There has been a general shift toward earlier treatment and less tolerance for clinically silent disease activity.

Although questions remain about ideal treatment strategies, consistent data have shown that patients should be treated early.

Aligning community pharmacy interventions with top-down findings, payers’ population health priorities, and identified unmet needs can help develop a sustainable pathway.

As value-based health care models become more widespread, these types of interventions will be important to demonstrate the value of pharmacist-embedded HSSPs.

Future potential directions include measuring the impact of clinical pharmacist interventions on referral utility, disease-specific clinical outcomes, patient satisfaction, medication adherence, and absenteeism.

Properly training staff and gaining stakeholder buy-in are crucial steps to successfully designing and launching a program to screen and address health-related social needs.

The results reinforce other real-world evidence from several broad infant immunization programs in the US, Spain, and France.

Prevention of acute cardiac events may be another consideration for future postlicensure studies of RSV vaccines.